BRIEF-Astrazeneca announced new results data evaluating cost-effectiveness of synagis

* Astrazeneca - announced new results data evaluating cost-effectiveness of synagis for respiratory syncytial virus in preterm infants 29-34 weeks gestational age
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.